John F Robertson
Overview
Explore the profile of John F Robertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1000
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergamino M, Lopez-Knowles E, Morani G, Tovey H, Kilburn L, Schuster E, et al.
EBioMedicine
. 2022 Aug;
83:104205.
PMID: 35985932
Background: Oestrogen receptor positive/ human epidermal growth factor receptor positive (ER+/HER2+) breast cancers (BCs) are less responsive to endocrine therapy than ER+/HER2- tumours. Mechanisms underpinning the differential behaviour of ER+HER2+...
2.
Garreffa E, Hamad A, OSullivan C, Hazim A, York J, Puri S, et al.
Eur J Cancer
. 2021 Nov;
159:38-51.
PMID: 34731748
Purpose: Over 1 billion doses of COVID-19 vaccines have been already administered across the United States, the United Kingdom and the European Union at the time of writing. Furthermore, 1.82...
3.
Hutcheson I, Knowlden J, Hiscox S, Barrow D, Gee J, Robertson J, et al.
Breast Cancer Res
. 2018 Sep;
20(1):98.
PMID: 30165904
After the publication of this work [1], an error was noticed in Fig. 2b and Fig. 4b as well as Fig. 4b. and Fig. 5d. Images of the ERK1/2 blots...
4.
Knowlden J, Gee J, Barrow D, Robertson J, Ellis I, Nicholson R, et al.
Breast Cancer Res
. 2011 Sep;
13(5):R93.
PMID: 21939528
Introduction: Recently we reported that insulin receptor substrate 1 (IRS-1), classically an adaptor protein for the insulin-like growth factor type I receptor (IGF-IR), associates with the epidermal growth factor receptor...
5.
Abd Hamid U, Royle L, Saldova R, Radcliffe C, Harvey D, Storr S, et al.
Glycobiology
. 2008 Sep;
18(12):1105-18.
PMID: 18818422
Aberrant glycosylation on glycoproteins that are either presented on the surface or secreted by cancer cells is a potential source of disease biomarkers and provides insights into disease pathogenesis. N-Glycans...
6.
Shaaban A, Green A, Karthik S, Alizadeh Y, Hughes T, Harkins L, et al.
Clin Cancer Res
. 2008 Aug;
14(16):5228-35.
PMID: 18698041
Purpose: Previous conflicting results about the prognostic significance of estrogen receptor (ER)-beta in breast cancer may be explained by contribution of isoforms, of which five exist. Our aim was to...
7.
Storr S, Royle L, Chapman C, Abd Hamid U, Robertson J, Murray A, et al.
Glycobiology
. 2008 Mar;
18(6):456-62.
PMID: 18332077
MUC1 is a high molecular weight glycoprotein that is overexpressed in breast cancer. Aberrant O-linked glycosylation of MUC1 in cancer has been implicated in disease progression. We investigated the O-linked...
8.
Hutcheson I, Knowlden J, Hiscox S, Barrow D, Gee J, Robertson J, et al.
Breast Cancer Res
. 2007 Aug;
9(4):R50.
PMID: 17686159
Introduction: Resistance to anti-epidermal growth factor receptor (anti-EGFR) therapies is an emerging clinical problem. The efficacy of anti-EGFR therapies can be influenced by the presence of heregulins (HRGs), which can...
9.
Parsy C, Chapman C, Barnes A, Robertson J, Murray A
J Chromatogr B Analyt Technol Biomed Life Sci
. 2007 Apr;
853(1-2):314-9.
PMID: 17459787
As part of a study to purify the internal domain of HER2 (ICD) from recombinant expression, through metal immobilised affinity chromatography (IMAC), we encountered a contaminant, SlyD, a 29 kDa...
10.
Rakha E, El-Sayed M, Green A, Lee A, Robertson J, Ellis I
Cancer
. 2006 Dec;
109(1):25-32.
PMID: 17146782
Background: Triple-negative breast cancer (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) is a high risk breast cancer that lacks the benefit of specific therapy that targets these proteins. Methods: In this...